PPM1D and diffuse large B-cell lymphoma: A study involving 85 patients with relapsed/refractory DLBCL, with a 20% prevalence of the PPM1D gene mutation, revealed that CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred at similar rates in both mutation-positive and mutation-negative patients.